AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00096356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo & Vitamin E
Study NCT00096356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Vitamin E
Study NCT01008423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.
Study NCT01008423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
Study NCT03762096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: 1 gram, twice a day by mouth Transmax (Biotivia)
Study NCT03762096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00645450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
Study NCT00645450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly doses of placebo (inactive pill) following recollection of traumatic memory
Study NCT02500940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Neoadjuvant chemotherapy regimen with cisplatin
Study NCT02500940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Neoadjuvant chemotherapy regimen with cisplatin
Study NCT02500940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Neoadjuvant chemotherapy regimen with Fluorouracil
Study NCT02500940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Neoadjuvant chemotherapy regimen with Fluorouracil
Study NCT02500940 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Intensity-Modulated Radiation Therapy
Study NCT02500940 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Intensity-Modulated Radiation Therapy
Study NCT02500940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Neoadjuvant chemotherapy regimen with Leucovorin
Study NCT02890641 — intervention group
Intervention type: GENETIC
Intervention: Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
Description: Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
Study NCT00496938 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XIENCE V®/ XIENCE PRIME™
Description: Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
Study NCT02560025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Study NCT02560025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02560025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02560025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Can be used in place of idarubicin
Study NCT01094522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: 0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.
Study NCT01094522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain.
Study NCT00439816 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group Visits
Study NCT01687725 — intervention group
Intervention type: DEVICE
Intervention: Renal denervation using Symplicity Catheter system
Description: percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
Study NCT04409860 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
Study NCT04409860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Radiation concurrent platinum-containing chemotherapy (cisplatin or carboplatin)
Study NCT04409860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: The regimen of adjuvant chemotherapy following CCRT is Paclitaxel(150mg/m2 D1), Cisplatin(60mg/m2 D1) , q3w, three cycles.
Study NCT01886989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa polyphenols
Description: Cocoa polyphenols (960mg) reconstituted in water
Study NCT01886989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa polyphenols
Description: Cocoa polyphenols (960mg) reconstituted in water
Study NCT00852839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match oromucosal formulation of 552-02
Study NCT00852839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 552-02
Description: The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
Study NCT01106716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV Infusion
Study NCT01106716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-1678
Description: KAI-1678 IV Infusion
Study NCT01106716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine
Study NCT03854994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study NCT04241900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shuttle run test
Description: At the shuttle run test, participants were required to run between two lines 20 meters apart, while keeping pace with audio signals emitted from a pre-recorded CD. The frequency of the sound signals increases in such way that running speed was increased by 0.5 km h-1 each minute from the starting speed 8.5 km h-1.
Study NCT02034409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Low Intensity Ultrasound
Description: 20 minutes daily for 48 weeks
Study NCT02034409 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: 20 minutes daily for 48 weeks
Study NCT02047721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
Study NCT02047721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by \~2000 kcal/week.
Study NCT03047824 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravascular continuous monitoring
Description: Bedside usual insulin therapy guided by continuous glucose monitoring
Study NCT03047824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Bedside usual insulin therapy guided by intemittent glucose monitoring
Study NCT02082756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium viable pharmaceutics
Study NCT02082756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride
Study NCT02894697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI with BVS
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
Study NCT02894697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-guided PCI with BVS
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
Study NCT01798160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB TACE
Description: DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
Study NCT01798160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
Study NCT03952949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Option While Online Grocery Shopping
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age.
Study NCT03952949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York).
Study NCT00886847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Needle Tissue Collections
Description: Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
Study NCT00638638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: * Abciximab: 0.25 mg/Kg bolus~* Abciximab placebo bolus~* Abciximab infusion 10 µg/Kg/min
Study NCT00638638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab placebo
Description: * Abciximab placebo Bolus~* Abciximab: 0.25 mg/Kg bolus~* Abciximab infusion 10 µg/Kg/min
Study NCT01234935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT01234935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01234935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01234935 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study NCT01234935 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study NCT01234935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT03675854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 3 weeks
Study NCT03675854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: 3 weeks
Study NCT00160667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes.
Study NCT00160667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes.
Study NCT00985777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E δ-Tocotrienol
Description: Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
Study NCT01311167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Daily administration of 2 mg of dexamethasone for 4 days
Study NCT01311167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of 2 mg of placebo for 4 days
Study NCT02594020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: air abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
Study NCT02594020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sono abrasion
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
Study NCT02594020 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: dental bur
Description: already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
Study NCT04157673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability. This intervention will be introduced following a 6-week, 8-week or 10-week baseline period.
Study NCT00731926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice a day for 1 month
Study NCT01208363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cowpea fortified with NaFeEDTA, in form of Toubani.
Description: 66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
Study NCT02473146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Study NCT00831493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation (Radiation Therapy)
Description: Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
Study NCT00831493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
Study NCT01420094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Description: Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter \[mL\]) between 1-4 hours post dental surgery.
Study NCT01420094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen (Tylenol extra strength)
Description: Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Study NCT01420094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
Study NCT02873949 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Crevicular samples (1-10µl)
Description: In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site
Study NCT02873949 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva samples (1ml)
Study NCT02873949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Etiologic treatment
Description: education on oral hygiene, scaling and root planing
Study NCT02873949 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Psychometric tests
Description: Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
Study NCT00022646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00022646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study NCT02079272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Helical tomotherapy for breast cancer
Description: 1. At baseline, before helical tomotherapy is performed, for each included woman will have:~   * measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, ..., microparticles and miRNA)~  * cardiologic examination including echocardiography for measurement of strain and strain rate~  * a CT coronary angiogram for measurement of coronary plaque indexes~2. Helical tomotherapy will be performed for all women included in the cohort.~3. At the end of tomotherapy, follow-up will include:~   * measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~  * cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~  * A CT coronary angiogram 24 months after radiotherapy
Study NCT03013309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health
Description: A parent-training intervention to improve child health and prevent/manage obesity
Study NCT03013309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual
Study NCT02806141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized plus intravenous colistin
Description: Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
Study NCT02806141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colistin
Description: Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
Study NCT02024789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally twice daily, 26 weeks
Study NCT02024789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: 120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Study NCT02024789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1662
Description: 240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
Study NCT01208363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Cowpea fortified with NaFeEDTA, in form of Toubani.
Description: 66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
Study NCT03407365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 Week Exercise Program
Description: Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
Study NCT03407365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DVD Program After 10 Weeks
Description: If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
Study NCT03189888 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: apheresis
Study NCT02924038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA950
Description: IMA950 vaccine
Study NCT02924038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly-ICLC
Description: poly-ICLC vaccine
Study NCT02924038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varlilumab
Description: Intravenous solution
Study NCT04063358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.5 MG Per 0.05 ML Injection
Study NCT04063358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis 0.5 MG Per 0.05 ML Injection
Study NCT01888081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-dmDT390-bisFv(UCHT1) (Resimmune®)
Study NCT01888081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ionizing Radiation